FDA approves GENGLYCOS as first gene therapy for glycogen storage disease type Ia
The approval introduces the first therapy designed to address the underlying cause of glycogen storage disease type Ia, offering a one-time gene therapy option for eligible patients aged eight years and older.
The US Food and Drug Administration (FDA) has granted accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr, also known as DTX401) for use alongside nutritional management to reduce daily cornstarch intake in adults and paediatric patients aged eight years and older with glycogen storage disease type Ia (GSDIa), making it the first approved treatment designed to address the disease's underlying cause. The approval provides a new therapeutic option for patients who currently rely on lifelong dietary management, although continued clinical follow-up is required to confirm long-term benefit under the accelerated approval pathway.
Field | Content |
Alert Type | Drug Approval |
Drug Name | GENGLYCOS (pariglasgene brecaparvovec-opnr; DTX401) |
Indication | Adjunct to nutritional management to reduce daily cornstarch intake in adults and paediatric patients aged eight years and older with glycogen storage disease type Ia (GSDIa). (U.S. Food and Drug Administration) |
Therapy Area(s) | Rare Diseases; Metabolic Disorders; Gene Therapy |
Geography | United States (FDA) |
What Happened | On 19 August 2026, the FDA granted accelerated approval to GENGLYCOS, an AAV8-based gene therapy developed by Ultragenyx, for adults and paediatric patients aged eight years and older with GSDIa. The one-time treatment delivers a functional G6PC gene to the liver to address the enzyme deficiency underlying the disease. It is the first approved therapy designed to target the root cause of GSDIa and the first gene therapy approved for this indication. The approval was supported by Phase III data demonstrating reduced reliance on dietary cornstarch and was accompanied by a post-marketing requirement to further confirm clinical benefit. (U.S. Food and Drug Administration) |
Why It Matters | Until now, management of GSDIa has depended on strict lifelong dietary control and frequent cornstarch dosing to prevent hypoglycaemia. GENGLYCOS offers a one-time gene therapy designed to restore glucose regulation by addressing the underlying enzyme deficiency, although long-term efficacy and safety will continue to be evaluated following accelerated approval. (U.S. Food and Drug Administration) |
Supporting Context | GSDIa is an ultra-rare inherited metabolic disorder caused by mutations affecting glucose-6-phosphatase activity, leading to impaired glucose release from the liver and severe metabolic complications. The approval was based on the Phase III GlucoGene study and the FDA also awarded Ultragenyx a Rare Pediatric Disease Priority Review Voucher. (U.S. Food and Drug Administration) |
Key Takeaway | FDA approval establishes GENGLYCOS as the first gene therapy and first disease-modifying treatment for GSDIa, providing a new option beyond lifelong dietary management. (U.S. Food and Drug Administration) |
What to Watch | Completion of the FDA-required post-marketing study to confirm long-term clinical benefit, commercial rollout in the US and regulatory decisions in other jurisdictions. (U.S. Food and Drug Administration) |
Primary Source | |
Relevant Date | 19 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言